Michelle Haber Explained

Michelle Haber
Birth Place:Liverpool, England
Nationality:Australian
Field:Paediatric cancer
Alma Mater:University of New South Wales
Known For:Identifying molecular targets in neuroblastoma and developing novel therapeutic approaches against them
Prizes:Doctor of Science honoris causa, UNSW (2008)

Michelle Haber is an Australian cancer researcher in the field of childhood cancer research.

Early life and education

Michelle Haber was born in Liverpool, England.

Haber attended Mount Scopus Memorial College in Melbourne and, when her family moved to Sydney, attended Moriah College, graduating in 1973.

She completed a clinical psychology degree at University of New South Wales and was awarded a University Medal. She obtained her PhD from the School of Pathology at the University of New South Wales in 1984 - her thesis was entitled "Structural analysis by BD-cellulose chromatography of mammalian DNA during repair, replication and degradation".[1]

Career

In 1982, during her PhD studies, Haber spent three months as Visiting Research Fellow at the Department of Molecular Virology in Hadassah Medical Centre, Hebrew University of Jerusalem. Her first postdoctoral position was as at Children’s Leukaemia and Cancer Research Unit, a precursor to Children's Cancer Institute then located at the Prince of Wales Children’s Hospital, Randwick. Having joined as a Staff Scientist in 1984,[2] she was promoted to Senior Research Fellow in 1992, Principal Research Fellow in 1996, Director in 2000 and Executive Director in 2003. Haber also holds a conjoint appointment as Professor in the Faculty of Medicine at the University of New South Wales.[3]

She serves as the executive director of Children's Cancer Institute[4] and is a professor at the School of Women’s and Children’s Health, University of New South Wales.[5] She is known for her discoveries in the area of chemotherapy resistance in neuroblastoma and for translating these discoveries into new therapeutics that are currently in clinical trials.[6]

Under her leadership Children's Cancer Institute, now located in the UNSW Lowy Cancer Research Centre,[7] has tripled in size and grown from a little known group to become the largest children’s cancer research facility in the region.[8]

Research

Haber’s early studies were amongst the first characterising the complex molecular mechanisms underlying therapy-related drug resistance.[9] [10] With her collaborators, she identified the relationship between high expression of multidrug transporter gene MRP1, and the malignant phenotype of neuroblastoma and poor clinical outcome.[11] [12] These studies provided the first definitive demonstration of clinical relevance of the MRP1 gene in solid tumours, resulting in a large international clinical study which confirmed the independent prognostic significance of MRP1 expression in neuroblastoma and established MRP1 inhibition as a potential new treatment for this disease.[13]

By high-throughput chemical screening of small molecule libraries, Haber and her colleagues have also developed novel MRP1 inhibitors and patented and licensed the compounds for the treatment of neuroblastoma and other MRP1-associated malignancies. This led to a $3.1M award from the Australian Cancer Research Foundation to establish a Drug Discovery Centre for Childhood Cancer in the UNSW Lowy Cancer Research Centre, which is currently developing a pipeline of potential new drugs for treating childhood and adult malignancies.

Haber and her collaborators have also identified the role of ATP-binding cassette transporter genes (ABC transporters) in neuroblastoma biology, demonstrating that their expression predicts for poor clinical outcome in neuroblastoma[14] but, unexpectedly, this phenomenon was not due to the ABC proteins’ role in drug transport, but through an independent pathway that influences fundamental aspects of tumour biology. A further study on ovarian cancer and ABCA1[15] has extended the discovery to common adult cancers.

Service to the scientific community

Haber is a long-term member of the International Neuroblastoma Risk Group Committee, which makes recommendations regarding standardised protocols and best practice for identifying/utilising prognostic indicators for neuroblastoma treatment risk assessment.[16]

From 2006 to 2014, Haber has served on the steering committee of the Advances in Neuroblastoma Research Association (ANRA), the peak international body for neuroblastoma research[17] and was president of this organisation from 2010 to 2012.

In 2011, Haber also played a key role in establishment of the Kids Cancer Alliance and currently serves on this organization's executive management committee.[18]

Haber is convenor of the 2016 Advances in Neuroblastoma Research conference in Cairns, one of the largest specialist childhood cancer conferences internationally.[19]

Recognition and awards

Notes and References

  1. Structural Analysis by BD-cellulose Chromatography of Mammalian DNA During Repair, Replication and Degradation . . 1984 . 26 June 2017 . Haber, Michelle .
  2. Web site: Paediatrio - Professor Michelle Haber AM BSc (Psych) (Hons), PhD, Hon DSc (UNSW) FAHMS. 19 Sep 2017.
  3. Web site: School of Women's and Children's Health - Professor Michelle Haber. 19 Sep 2017.
  4. Web site: Children's Cancer Institute | Curing Children's Cancer . Ccia.org.au . 2015-05-03 . 2017-06-30.
  5. Web site: Professor Michelle Haber | Medicine . Med.unsw.edu.au . 2017-06-30.
  6. Web site: Professor Glenn Marshall | National Health and Medical Research Council . 2014-08-14 . dead . https://web.archive.org/web/20140911020540/https://www.nhmrc.gov.au/research-highlights/profile/professor-glenn-marshall . 2014-09-11 .
  7. Web site: Welcome - Lowy Cancer Research Centre. lowycancerresearchcentre.unsw.edu.au. 26 June 2017.
  8. Web site: Our story - Children's Cancer Institute . ccia.org.au . 3 May 2015 . 30 Jun 2017.
  9. 10.1093/jnci/81.16.1250 . Resistance to Drugs Associated with the Multidrug Resistance Phenotype Following Selection with High-Concentration Methotrexate . JNCI Journal of the National Cancer Institute . 81 . 16 . 1250–1254 . 1989 . Haber . M. . Reed . C.. Maria Kavallaris . Kavallaris . M. . Norris . M. D. . Stewart . B. W. . 2754745 .
  10. 2569932 . Atypical Multidrug Resistance in a Therapy-induced Drug-resistant Human Leukemia Cell Line (LALW-2): Resistance to Vinca Alkaloids Independent of P-Glycoprotein . Cancer Research . 49 . 19 . 5281–5287 . October 1989 . Stewart . Bernard W. . White . Les . Davey . Ross A. . Bell . David R. . Kavallaris . Maria . Norris . Murray D. . Haber . Michelle .
  11. 7923112 . 1994 . Bordow . S. B. . Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma . Cancer Research . 54 . 19 . 5036–40 . Haber . M. . Madafiglio . J. . Cheung . B. . Marshall . G. M. . Norris . M. D. .
  12. 10.1056/nejm199601253340405 . 8532000 . Expression of the Gene for Multidrug-Resistance–Associated Protein and Outcome in Patients with Neuroblastoma . New England Journal of Medicine . 334 . 4 . 231–238 . 1996 . Norris . Murray D. . Bordow . Sharon B. . Marshall . Glenn M. . Haber . Paul S. . Cohn . Susan L. . Haber . Michelle . free .
  13. 10.1200/JCO.2005.01.6196 . 16575006 . Association of High-LevelMRP1Expression with Poor Clinical Outcome in a Large Prospective Study of Primary Neuroblastoma . Journal of Clinical Oncology . 24 . 10 . 1546–1553 . 2006 . Haber . Michelle . Smith . Janice . Bordow . Sharon B. . Flemming . Claudia . Cohn . Susan L. . London . Wendy B. . Marshall . Glenn M. . Norris . Murray D. .
  14. Henderson, M. J. . Haber, M. . Porro, A. . etal. 2011 . ABCC multi drug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux . Journal of the National Cancer Institute . 103 . 16 . 1236–51 . 10.1093/jnci/djr256. 21799180 . 3156802 .
  15. Hedditch, E. L. . etal. 2014 . ABCA transporter gene expression is associated with poor outcome in epithelial ovarian cancer . Journal of the National Cancer Institute . 106 . 7 . dju149 . 10.1093/jnci/dju149 . 24957074 . 4110473 . 2014 .
  16. Web site: Leadership - International Neuroblastoma Risk Group Task Force. inrgdb.org. 26 June 2017.
  17. Web site: Advances in Neuroblastoma Research Association Meetings. Anrmeeting.org. 26 June 2017.
  18. Web site: Home . Kids Cancer Alliance . 2017-06-30.
  19. Web site: Home » ANR 2016. anr2016.org. 26 June 2017.
  20. Web site: It's an Honour - Honours - Search Australian Honours. Itsanhonour.gov.au. 26 June 2017.
  21. Web site: Scientist of the Year. 24 November 2011. Newsroom.unsw.edu.au. 26 June 2017.
  22. Web site: Michelle Haber AM. https://web.archive.org/web/20220209131651/https://www.australianoftheyear.org.au/recipients/chris-riley/816/. dead. 9 February 2022. Australianofotheyear.org.au. 9 February 2022.
  23. Web site: NSW Premier's Awards for Outstanding Cancer Research - Cancer Institute NSW . Cancerinstitute.org.au . 2016-09-07 . 2017-06-30.
  24. Web site: Ten of the Best 2012 | National Health and Medical Research Council . 2014-08-14 . dead . https://web.archive.org/web/20140212213058/https://www.nhmrc.gov.au/research-highlights/ten-of-the-best/2012 . 2014-02-12 .
  25. 10.1016/S0140-6736(13)61107-1 . Profile: CCIA—teaming up to target paediatric cancer . The Lancet . 381 . 9880 . 1804 . 2013 . Kirby . Tony . 23717834 . 35893252 . free .
  26. Web site: 2013 Finalists (Eureka Prizes) - Australian Museum. australianmuseum.net.au. 26 June 2017.
  27. Web site: 2014 NSW Outstanding Cancer Researcher of the Year Announced - Cancer Institute NSW . Cancerinstitute.org.au . 2014-08-22 . 2017-06-30.
  28. Web site: Fellowship - AAHMS – Australian Academy of Health and Medical Sciences. Aahms.org. 26 June 2017.
  29. Web site: 2022-05-26 . Academy announces 2022 Fellows for outstanding contributions to science . 2022-05-25 . Australian Academy of Science . en.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Michelle Haber".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.